EN
Home/Guides/Stopping
Guide 9 of 9 · Stage: Live with it

What happens when you stop a GLP-1 like Wegovy or Zepbound?

Weight regain, blood sugar, lower doses, the label stopping rules, the cost over years in $, and how to stop safely.

The short answer

Most people regain much of the lost weight within a year of stopping a GLP-1 medicine such as semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro). Blood sugar and blood pressure tend to rise again too. Stopping can still be the right choice, for example if the medicine isn't working, causes side effects you can't live with, or costs more than you can keep paying. Plan it with your doctor, especially if you have diabetes.

Key facts

Weight after stopping
About two-thirds of the loss came back within a year in the main semaglutide trial1
How fast
About 0.8 kg (nearly 2 lb) a month after semaglutide or tirzepatide, on average5
Label stopping rules
Saxenda: stop if under 4% lost at 16 weeks. Wegovy and Zepbound labels set no fixed cut-off15,13,16
Lower dose instead
Tested for tirzepatide only; kept most, not all, of the loss10
Pregnancy plans
Stop Wegovy at least 2 months before trying, says its label; for tirzepatide, the European label says at least 1 month13,17
On this page
  1. What happens to your weight when you stop?
  2. What happens to blood sugar, blood pressure and cholesterol?
  3. Why does the weight come back?
  4. Can you take a lower dose, or taper off?
  5. What helps keep weight off?
  6. What does staying on it cost over years?
  7. When is stopping the right call?
  8. How do you stop safely?
  9. What if you miss doses or can't get supply?
  10. Questions people ask

What happens to your weight when you stop?

In trials, most people regained much of the weight they had lost within a year of stopping. On average, they did not go all the way back to where they started.

The clearest test is a one-year follow-up of the main semaglutide trial (the STEP 1 extension). It followed 327 people for a year after treatment stopped: 228 had been on semaglutide 2.4 mg and the rest on a dummy injection.1

STEP 1 extensionSemaglutide 2.4 mg, then stopped

327 people, followed for a year after treatment ended.1 For someone who started at 200 lb:

165.4 lbafter 68 weeks on semaglutide: 34.6 lb lost (−17.3%)
+23.2 lbcame back in the year after stopping, about two-thirds of the loss (+11.6% of starting weight)
188.8 lba year after stopping: still 11.2 lb below the start (−5.6%). Dummy-injection group: 199.8 lb

So about two-thirds of the lost weight came back. For a 200 lb (91 kg) person, that means losing about 35 lb (16 kg), then regaining about 23 lb (10 kg).1 About half the people (48%) were still at least 5% lighter than at the start.1

Weight change before and after stopping semaglutide (STEP 1)

Semaglutide 2.4 mgDummy injection

Average change from starting weight. Lines join the 3 measured points; the real path between them was curved. Source: STEP 1 extension.1

Two more trials tested this differently. Everyone took the medicine first. Then, at random, some carried on and the rest were switched to a dummy injection without knowing. So the gap between the two groups shows what stopping does:

STEP 4Semaglutide 2.4 mg

Everyone took it for 20 weeks, then half switched to a dummy injection for 48 weeks.2 For someone who started at 200 lb:

178.8 lbat the switch, after 20 weeks: 21.2 lb lost (−10.6%)
190.0 lbswitched to the dummy: 11.2 lb of the 21.2 lb came back (−5.0% vs start)
164.7 lbkept taking it: another 14.1 lb off (−7.9% more)
SURMOUNT-4Tirzepatide, highest dose people could take

Everyone took it for 36 weeks, then half switched to a dummy injection for 52 weeks.3 For someone who started at 200 lb:

158.2 lbat the switch, after 36 weeks: 41.8 lb lost (−20.9%)
180.2 lbswitched to the dummy: 22.0 lb of the 41.8 lb came back (−9.9% vs start)
149.5 lbkept taking it: another 8.7 lb off (−5.5% more)

The lb figures are our arithmetic for one example person starting at 200 lb, using each trial's average percentages; real people varied a lot. In both trials about half the lost weight came back after switching. The trials also report regain of 6.9% (STEP 4) and 14.0% (SURMOUNT-4), but those are measured from the lower weight at the switch, so they look different.2,3

Two 2026 reviews pooled many studies. A BMJ review of 37 studies (9,341 people) found weight came back at about 0.8 kg (nearly 2 lb) a month after semaglutide or tirzepatide.5 It projected a return to starting weight in about 1.5 years. That is an estimate: no study of these two drugs followed people for more than a year.5

A second review estimated that 60% of the lost weight returns in the first year. It predicted regain would level off at about 75%, not 100%.6 So the two reviews disagree: one projects a full return to starting weight, the other a partial one.5,6 These are averages. In one tirzepatide analysis, 1 in 6 people regained less than a quarter of what they lost.4

What happens to blood sugar, blood pressure and cholesterol?

They tend to drift back towards where they were before treatment. The more weight comes back, the more they rise.

In STEP 1, blood pressure was back at its starting level a year after stopping. Average blood sugar (HbA1c, a 3-month sugar test) and cholesterol also rose again.1

In the tirzepatide trial above (SURMOUNT-4), people who regained the most saw the biggest rises. Top (systolic) blood pressure went up by 7 to 10 points, depending on how much weight came back.4 People who kept most of the weight off kept some benefits, such as lower blood fats (triglycerides).4

If you have type 2 diabetes, this matters most. In people with diabetes, HbA1c rose by an average of 0.65 points after stopping: for example, from 7.0% to about 7.65%.7 See how to stop safely.

The BMJ review projected that all these heart and sugar markers would be back at their starting levels within about 1.4 years.5

Why does the weight come back?

The medicine was holding your appetite down. When it wears off, hunger returns, and your body also pushes to regain lost weight.

Half of each semaglutide dose is still in the body after about a week. It stays in the blood for about 5 to 7 weeks after the last injection.13 As it goes, the feeling of fullness it gave goes too.

Losing weight by any route changes your hunger hormones. In one study of dieting, these changes and stronger hunger were still there a year later.8 The body acts as if it wants the weight back.

This is why experts now call obesity a long-term (chronic) condition, like high blood pressure. The WHO calls it "a chronic, relapsing disease requiring lifelong care".9 The STEP 1 authors said their results suggest ongoing treatment is needed to keep the benefits.1

Regain is not a personal failure. The BMJ review found weight came back faster after medicines than after diet programs alone, whatever the amount first lost.5

Can you take a lower dose, or taper off?

One good trial says a lower tirzepatide dose keeps most of the weight off. For semaglutide, and for tapering to zero, the evidence is thin.

One trial (SURMOUNT-MAINTAIN) took 378 US adults who had lost weight on tirzepatide 10 or 15 mg. They were split into 3 groups for a year: full dose, 5 mg, or a dummy injection.10

SURMOUNT-MAINTAINTirzepatide: full dose, 5 mg or dummy injection

378 adults.10 Everyone first lost weight on tirzepatide. Then they were split into three groups for a year: kept the full dose, dropped to a low 5 mg dose, or switched to a dummy injection. For someone who started at 200 lb:

Kept the full dose156.2 lba year later: 43.8 lb below the start (−21.9%)8 in 100 put back half or more of what they had lost
Dropped to 5 mg166.8 lba year later: 33.2 lb below the start (−16.6%)25 in 100 put back half or more of what they had lost
Switched to a dummy injection180.2 lba year later: 19.8 lb below the start (−9.9%)67 in 100 put back half or more of what they had lost

Most people in this trial were white women.10 So results may differ for men, and for people of other ethnic backgrounds. Eli Lilly, which makes tirzepatide, paid for it.10 Staying on a medicine also means staying with its side effects. In the semaglutide trial above (STEP 4), 42% of people who continued semaglutide had stomach side effects, vs 26% on a dummy injection.2

For semaglutide, no finished trial has tested a lower maintenance dose or a slow taper. The first randomized taper trial, in China, had not started recruiting as of October 2026.11 In real life, many people already use lower doses. In one Danish family-doctor practice, 40% of people still on semaglutide after a year took 1 mg or less.11

The WHO's 2025 guideline names "maintenance and discontinuation" as areas where long-term data are limited.9 So a taper plan is your doctor's judgement, not a proven method.

The risks, in brief Staying on a GLP-1 long term means living with its risks:
  • Common: feeling sick, vomiting, diarrhea and constipation, mostly when the dose goes up.
  • Rare but serious: inflammation of the pancreas (pancreatitis) and gallbladder problems.
  • Vomiting or diarrhea can dry you out (dehydration) and harm the kidneys.
  • Not for people with a personal or family history of a rare thyroid cancer (MTC) or MEN2.
  • Not for use in pregnancy.
Read Guide 5: Side effects and risks →

What helps keep weight off?

Keeping up exercise and support with eating and habits help most. Nothing yet fully replaces the medicine.

A Danish trial gave 195 people who had just lost weight a year of supervised exercise, a GLP-1 medicine (liraglutide), both, or neither. Then all treatment stopped, and 109 of them were weighed again a year later.12

  • Medicine plus exercise, against the medicine alone: about 5.5 lb (2.5 kg) less regain. That difference was small enough that it could have been chance.12
  • Exercise alone, against the medicine alone: the medicine-only group regained about 13 lb (6 kg) more.12

So exercise during treatment looks helpful, but this one small trial can't prove how much it adds once you stop the medicine.

Some evidenceKeep exercisingStarted while on the medicine, and kept going after. Helpful, but tested in only one small trial.12
RecommendedBehavioral supportWHO advises structured help with eating and habits alongside GLP-1s.9
PromisingA lower doseTested for tirzepatide only, in one trial.10
UnprovenSlow tapering to zeroNo finished randomized trial yet.11

That exercise trial used liraglutide, an older daily GLP-1, and followed 109 people.12 Protein and strength training to protect muscle are covered in Guide 8: Life on a GLP-1.

What does staying on it cost over years?

If you need it long term, the cost is long term too. With insurance, it's your copay for as long as your plan covers it. Paying yourself at the makers' current self-pay prices, 5 years of Zepbound comes to about $26,000 at 5 mg and $29,000 at the higher doses.

These are examples, not a price list. A Zepbound or Wegovy pen fill holds 4 weekly doses, so a year is 13 fills; a pill fill is 30 tablets.18,19 Prices checked Oct 12, 2026; several offers end on December 31, 2026.

Medicare GLP-1 Bridge, if you qualify (ends Dec 31, 2027)20
Per month$50
1 year$600
3 yearsNot yet known
5 yearsNot yet known
Wegovy pill 25 mg, self-pay19
Per 30 tablets$299
1 year (12 fills)$3,588
3 years$10,764
5 years$17,940
Wegovy pen, any dose up to 2.4 mg, self-pay19
Per 4 weeks$349
1 year$4,537
3 years$13,611
5 years$22,685
Zepbound 5 mg, self-pay18
Per 4 weeks$399
1 year$5,187
3 years$15,561
5 years$25,935
Zepbound 7.5–15 mg, self-pay, refilled within 45 days18
Per 4 weeks$449
1 year$5,837
3 years$17,511
5 years$29,185

Medicine only, listed by brand in alphabetical order, not ranked. Telehealth services and clinics may add membership, visit or shipping fees.

How we worked out these figures

Our arithmetic: the maker's self-pay price × 13 fills a year for weekly pens (52 weekly doses), or × 12 fills a year for the 30-tablet pill pack, then × 3 and × 5. We assume prices stay the same, which they may not.18,19 The Medicare GLP-1 Bridge is a temporary program that ends on December 31, 2027, so we don't project it past then.20

Coverage can change. Employer plans can drop or change the brands they cover, and Medicare's Bridge is temporary.20,21 Plan for what you'd do if your coverage ended.

In one Danish family-doctor practice, 38% had stopped semaglutide within a year, for all reasons.11 Before you start, ask whether you could afford it for years, not months. Guide 7 explains how providers charge.

When is stopping the right call?

Stopping is a reasonable choice in several situations. A medicine that harms you, isn't working, or can't be paid for is not worth staying on. These are the common reasons.

  • Side effects you can't live with, or a serious one such as pancreatitis. Guide 5 lists the warning signs.
  • Planning a pregnancy. The Wegovy label says to stop at least 2 months before a planned pregnancy, because semaglutide stays in the body a long time.13 The European tirzepatide label says at least 1 month.17 The tirzepatide label warns it may harm an unborn baby.14
  • An operation or sedation. These medicines slow the stomach. Rarely, people have breathed in stomach contents during anesthesia.13 The labels say to tell your surgeon you take one. They say there isn't enough data to know if pausing it helps.13,14
  • It isn't working. See the label rules below.
  • Cost, if paying is straining your budget, or your coverage ends.
  • It was never the right medicine for you, for example taken to lose a few pounds before a vacation, or bought without a proper prescription. See Guide 4.

The label stopping rules

US labels differ. For a 200 lb (91 kg) person, 4% is 8 lb (3.6 kg) and 5% is 10 lb (4.5 kg).

Liraglutide (Saxenda)Under 4% lost after 16 weeksStop, says the US label.15
Semaglutide (Wegovy)No fixed cut-offThe prescriber chooses the dose to stay on, based on response and how well you tolerate it.13
Tirzepatide (Zepbound)No fixed cut-offThe same: response and tolerability guide the dose.16

These rules are about whether a medicine is worth continuing. Falling short is not a personal failure, and your doctor can talk through other options.

How do you stop safely?

With your doctor, and with a plan for what comes next. Your weight, blood sugar and blood pressure will need watching for months.

1Talk to the person who prescribed it
2Agree a plan: stop, lower dose, or pause
3If diabetic: a replacement plan for sugar control
4Check weight, sugar and blood pressure in the months after

Our summary of the evidence on this page, not a clinical protocol.

Don't stop without first talking to the person who prescribed it, whether that's your own doctor or a telehealth service. Ask them for a plan for the months after.

If you have diabetes, stopping can push your HbA1c (a blood test of your average sugar over about 3 months) up.7 Your doctor may need to add or change another sugar medicine. Don't just stop and wait to see.

Keep the habits you built: regular exercise and the eating patterns that worked. They give you the best chance of holding on to some of the loss.12

What if you miss doses or can't get supply?

A short gap is usually fine. After a longer gap, ask your doctor before restarting, because you may need to restart on a lower dose.

Wegovy injection (US label): if one dose is missed and the next is more than 2 days away, take it as soon as you can; if less than 2 days away, skip it. If 2 or more doses in a row are missed, restart at a lower dose and step up again.13

Zepbound (US label): take a missed dose within 4 days. After that, skip it and take the next one on your usual day.16 The label gives no rule for restarting after a long gap. Ask your doctor what dose to restart on.

Don't restart at your old full dose after a long break without asking your doctor. Restarting counts as starting again, so the birth control advice applies too: with tirzepatide, switch from the pill or add a barrier method, such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase.16
US note: semaglutide and tirzepatide were in short supply from 2022; the FDA declared both shortages over by February 2025.22 If your medicine is out of stock, ask your prescriber before switching. Don't fill a gap with a compounded version or an unfamiliar seller: fake Ozempic pens have been found in the US supply chain.23

Questions people ask

Will all the weight come back if I stop?

Not always all of it. In the main semaglutide trial (STEP 1), people regained about two-thirds of the lost weight in the year after stopping, and ended 5.6% below their starting weight on average.1 Results vary a lot between people.4

Is there a rule for when to stop?

Only for Saxenda: its label says to stop if you haven't lost at least 4% after 16 weeks. The Wegovy and Zepbound labels leave it to you and your prescriber, based on how it's working.15,13,16

Can I stop and start again later?

Many people do, but plan it with your doctor. After 2 or more missed doses, the Wegovy label says to restart at a lower dose.13

Is it safe to just stop suddenly?

In the trials, people stopped all at once. What followed was a slow return of weight, blood sugar and blood pressure.1,5 If you have diabetes, you need a sugar plan first.

Can I take a lower dose instead of stopping?

For tirzepatide, one trial (SURMOUNT-MAINTAIN) found a 5 mg dose kept most of the loss, though less than the full dose.10 For semaglutide, there's no finished trial yet.11

How long before pregnancy should I stop?

At least 2 months for Wegovy, says its label. For tirzepatide, the European label says at least 1 month; the Zepbound label says to stop when pregnancy is recognized. Plan this with your doctor.13,17,16

Before you move on

  • Most people regain much of the weight within a year of stopping.
  • Blood sugar and blood pressure tend to rise again too.
  • Only the Saxenda label sets a cut-off; otherwise you and your prescriber judge how it's working.
  • A lower dose is tested for tirzepatide only; tapering is unproven.
  • Paying yourself at the makers' prices, 5 years can cost over $20,000.
  • Stop with your doctor; if diabetic, have a sugar plan first.
All 9 guides done

You've finished the 9 guides

Pick the path that fits you. Each one points to the parts that matter most for your situation.

Back to the homepage →
Was this guide easy to understand?

Sources

  1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–64. doi:10.1111/dom.14725
  2. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA, 2021;325(14):1414–25. doi:10.1001/jama.2021.3224
  3. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA, 2024;331(1):38–48. doi:10.1001/jama.2023.24945
  4. Horn DB et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal: a post hoc analysis of SURMOUNT-4. JAMA Internal Medicine, 2026;186(2):157–67. doi:10.1001/jamainternmed.2025.6112
  5. West S et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, January 7, 2026. doi:10.1136/bmj-2025-085304
  6. Budini B et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine, 2026;93:103796. doi:10.1016/j.eclinm.2026.103796
  7. Tzang CC et al. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine, 2025. doi:10.1016/j.eclinm.2025.103680
  8. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. NEJM, 2011;365:1597–604. doi:10.1056/NEJMoa1105816 (a diet study, not a GLP-1 study)
  9. Celletti F, Farrar J, De Regil L. World Health Organization guideline on the use and indications of GLP-1 therapies for the treatment of obesity in adults (December 2025). JAMA, 2026. doi:10.1001/jama.2025.24288
  10. Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). The Lancet, 2026. doi:10.1016/S0140-6736(26)00656-2. Funded by Eli Lilly.
  11. Skandov MD et al. Real-world use of semaglutide for weight management: dose titration, discontinuation patterns and weight changes. Diabetes, Obesity and Metabolism, 2026. doi:10.1111/dom.71092; and ClinicalTrials.gov NCT07783854 (semaglutide dose-tapering trial, not yet recruiting, checked Oct 5, 2026).
  12. Jensen SBK et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. eClinicalMedicine, 2024;69:102475. doi:10.1016/j.eclinm.2024.102475
  13. Novo Nordisk. Wegovy (semaglutide) injection and tablets, US prescribing information, revised June 2026: sections 2 (maintenance dose; missed doses), 5.10 (anesthesia), 8.3 (stop at least 2 months before a planned pregnancy), 12.3 (half-life). PDF
  14. Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised August 2026: 5.9 (anesthesia), 8.1 (pregnancy). uspl.lilly.com
  15. Novo Nordisk. Saxenda (liraglutide) US prescribing information, revised February 2026 ("discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight" 16 weeks after starting). PDF
  16. Eli Lilly. Zepbound (tirzepatide) US prescribing information, revised August 2026: sections 2 (maintenance dose; missed dose within 4 days), 8.1 (discontinue when pregnancy is recognized), 8.3 (oral contraceptives). uspl.lilly.com
  17. European Medicines Agency. Mounjaro (tirzepatide) summary of product characteristics, section 4.6 (stop at least 1 month before a planned pregnancy). PDF
  18. Eli Lilly. Zepbound coverage and savings (self-pay: 5 mg $399; 7.5–15 mg $449 with refills within 45 days). Checked October 12, 2026. zepbound.lilly.com
  19. Novo Nordisk. NovoCare Wegovy self-pay offer (pen $349 a month for all doses after the new-patient offer; pill 25 mg $299 a month; a month is 4 pens or 30 tablets). Checked October 12, 2026. novocare.com
  20. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge: information for prescribers ($50 copay; July 1, 2026, to December 31, 2027). Product No. 12235, June 2026. cms.gov
  21. Medicare.gov. Drug plan rules (plans can change their drug lists). Checked October 12, 2026. medicare.gov
  22. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved December 2024; semaglutide February 2025). Content current as of April 1, 2026. fda.gov
  23. FDA. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in US drug supply chain. Warnings of December 2023, April 2025 and December 2025. fda.gov
  24. FDA. MedWatch: the FDA safety information and adverse event reporting program (1-800-FDA-1088). Content current as of October 9, 2026. fda.gov

Last checked Oct 12, 2026 · Next review due Jan 2027 · Report an error

How this guide was made. Written by the GLP Guidebook team from the sources above: published trials, US and European product information, CMS and FDA pages, and the makers' published self-pay prices. We publish list prices and the makers' own prices only, never a seller's price. It's general information, not medical advice. Talk to a qualified doctor or pharmacist before starting, stopping or changing any medicine. In an emergency, call 911. Report side effects to the FDA's MedWatch program (1-800-FDA-1088).24 How we write